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Signal transductionInducible nitric oxide synthase (iNOS) and nitric oxide (NO) involve many pathophysiologic conditions. The
expression of iNOS is regulated at multiple stages. Presently, the regulatory details of iNOS signaling are still
unclear. This study aimed to investigate the regulatory role of C/EBPα and C/EBPβ in iNOS signaling pathway.
By employing the techniques such as EMSA, ChIP assay, site-directed mutagenesis, and siRNA silencing, the
relationship between iNOS and C/EBPα/C/EBPβ in rat hepatocytes was clariﬁed. iNOS promoter was the direct
transcriptional targets of the C/EBPα, C/EBPβ, and NF-κB binding proteins. There was the interactive inﬂuence
between NF-κB and C/EBPα/C/EBPβ. The expression of iNOS was modulated by C/EBPα/C/EBPβ transcription
factors. Moreover, the iNOS expression mediated glycochenodeoxycholate (GCDC)-induced apoptosis in
hepatocytes. C/EBPα/C/EBPβ binding proteins could affect the GCDC-induced apoptosis through iNOS
cascade. These ﬁndings indicate that C/EBPα and C/EBPβ regulate the iNOS expression, which may further
modify cell responses such as apoptosis and cell survival.l Center, Section of Pediatric
2, USA. Tel.: +1 312 942 3358;
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
iNOS/NO plays an important role in the regulation of many
physiological processes, such as in the immune system against
pathogens and in the cardiovascular system to dilate blood vessels
through the activation of guanylate cyclase [1,2]. In liver, the effect of
iNOS/NO is hepatic-protective as demonstrated in sepsis and ischemia
reperfusion [3]. The cytoprotective role of iNOS/NO can be best
exempliﬁed in a rodent model of endotoxemia. The addition of the
iNOS inhibitors signiﬁcantly increases hepatic damage [4]. The iNOS/
NO is apoptosis-resistant. NO suppresses apoptosis via interrupting
caspase activation and mitochondrial dysfunction [5]. NO protects
hepatocytes from TNF-alpha-induced apoptosis and hepatotoxicity in
vivo and in vitro. NO inhibits apoptosis through the increment in cyclic
GMP formation and the suppression of caspase activity by the S-
nitrosylation of the active site thiol [6]. The mitochondria-dependent
apoptotic signaling pathway is also suppressed by the S-nitrosylation
of caspase-8 and the inhibition of Bid cleavage by NO in hepatocytes
[7]. Besides having anti-apoptotic function, NO is pro-apoptotic as
well [8]. NO can increase TRAIL-induced cytotoxicity by facilitating the
mitochondria-mediated caspase signal transduction pathway [9].
Obviously, iNOS/NO plays a considerable role under pathophysiologic
conditions.Although the expression of iNOS is involved in chronic liver
disorders [10], regulation of iNOS expression in hepatocytes has not
been addressed thoroughly. The regulation of iNOS expression occurs
at multiple stages along the signaling pathway. Generally, the
regulation of iNOS can be classiﬁed into upstream transcriptional
factors and downstream posttranscriptional mechanisms. It is known
that iNOS expression requires the transcription factor NF-κB [11]. The
iNOS expression is down-regulated by steroids, TGF-β, the heat shock
response, p53, and NO itself [4]. In vivo hepatic iNOS induction is
differentially regulated by the typical acute-phase reactants [12]. The
constitutively generated NO maintains the hepatic microcirculation
and endothelial integrity. iNOS expression protects liver from
apoptotic cell death in sepsis and hepatitis, whereas NO potentiates
the hepatic oxidative injury in warm ischemia/reperfusion [13]. iNOS
inﬂuences liver function in different degrees under a variety of
pathophysiologic situation. iNOS/NO production can be either
beneﬁcial or detrimental. Accordingly, numerous mechanisms have
evolved to regulate iNOS expression during hepatocellular injury.
Study on iNOS/NO signaling may provide potential targets for the
treatment of liver injury.
The iNOS/NO signaling regulates the GCDC-induced hepatocyte
apoptosis, but some detailed links remain unclear. If iNOS is thought
of as a middle point during GCDC-caused apoptotic process, what are
the upstream transcriptional factors? What are the downstream
targeting molecules? It is crucial to know how iNOS is regulated in
hepatocytes. The current study emphasizes the relationship between
iNOS expression and regulatory transcription factors. It has been
known that NF-κB could bind the iNOS promoter to activate iNOS
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by other transcriptional nuclear factors such as AP-1, cJun, cFos, and so
on [14]. However, we do not knowwhether there are other regulatory
factors and how they function. Hepatocyte is a good cell type to study
apoptosis, but still has some limitations, e.g. the primary culture of
hepatocytes is hard to elucidate the interactions from in vivo
hepatocytes, Kuffer cells, and endothelial cells. Additionally, the
primary hepatocytes de-differentiate quickly and lose their ability to
transport bile acids fast. Thus, the actual experiments that address
GCDC-induced apoptosis in primary hepatocytes have to be per-
formed within limited hours after cell isolation. This short time frame
is not feasible for some experiments and increases difﬁculty in
reproducibility.
To investigate the regulation of iNOS signaling, GCDC was utilized
as an inducer to trigger apoptotic injury in rat hepatocytes. The iNOS
expression was analyzed at different levels. Endogenous iNOS,
transcriptionally regulated by C/EBPα and C/EBPβ, could modulate
the GCDC-induced apoptosis in primary hepatocytes. C/EBPs — iNOS
signaling pathway may be a future target for designing therapeutic
intervention in liver disease.2. Materials and methods
2.1. Hepatocyte isolation and culture
Hepatocytes were isolated from adult Sprague–Dawley rats along
standard liver perfusion procedure and cultured as described
previously [15,16]. Brieﬂy, hepatocytes were isolated through
collagenase perfusion, puriﬁed with repeated centrifugation, and
followed by further puriﬁcation over 30% Percoll. Highly puriﬁed
hepatocytes (N98% viability) were suspended in Williams medium E
containing 10% heat-inactivated calf serum. The cells were plated on
collagen-coated dishes at a density of 5×105 and placed at 37 °C in 5%
CO2/95% air. The cell treatment included iNOS-speciﬁc inhibitor N-(3-
(aminomethyl)benzyl)acetamidine (1400 W) (50 μM), NF-κb inhib-
itor BAY 11-7082 (30 μM), or GCDC (50 μM) as indicated.2.2. Rat iNOS promoter plasmid construct
The rat iNOS-Lucif construct was made as described (GenBank
accession number AF042085) [17]. A 2.1-kb fragment was ampliﬁed
from Sprague–Dawley liver genomic DNA by PCR using the published
primers (forward, 5′-CAG CCA AGT ATT CCA AAG CAA-3′; reverse, 5′-
AGT CCA GTC CCC TCA CCA A-3′) and its identity was conﬁrmed by
DNA sequence analysis. This 2.1-kb fragment was ligated into the
pGL4 basic luciferase vector for transient transfection. Renilla
luciferase was used as the internal control from Promega. The
QuikChange site-directed mutagenesis kit (Stratagene) was utilized
to delete the exact NF-κb, C/EBPα, or C/EBPβ binding sites as
described previously [18].2.3. Transient transfection and luciferase assay
Transient transfection was accomplished using a kit from Qiagen
according to the manufacturer's protocol. Subconﬂuent cultures of
HepG2 cells (2×105) were transfected with 2 μg of each reporter
iNOS-Lucif vector and a plasmid expressing the enzyme Renilla
luciferase as an internal control. After overnight recovery, the cells
were lysed using a commercially available kit (Promega). Fireﬂy and
Renilla luciferase activities were assayed by the use of the Dual
Luciferase Reporter System (Promega). The ﬁreﬂy luciferase activity
was normalized by Renilla luciferase activity present in each sample
and expressed as -fold induction relative to control.2.4. siRNA and transfection
The double stranded siRNAs against C/EBPα (GenBank accession
no. NM_012524) or C/EBPβ (GenBank accession no. NM_024125)
were consisted of pools of three target-speciﬁc 19–25 nt siRNAs in
accordance with the Ambion web-based criteria. The scrambled
siRNA, 5′-AUUGUAUGCGAUCGCAGAC-3′, was applied for nonspeciﬁc
silencing effects [19]. Hepatocytes were seeded in 6-well plate at
5×105 cells for 6 h prior to transfection. The cells were transfected
with 200 nM double-stranded siRNA and lipophilic transfection
reagent (Lipofectamine 2000, Invitrogen, Carlsbad, CA). The Williams
Emediumwas replaced 16 h post transfection. The cells were exposed
to 50 μM of GCDC and harvested in 4 h.
2.5. Caspase assay
100 μg of cell lysate was utilized to assay the activities of caspase-
3. Caspase assay kit was purchased from Calbiochem. The reaction
system employed the colorimetric substrate IETD-pNA and the
caspase-3 activity was calculated as pmol/min [15].
2.6. TUNEL assay
The TdT-FragEL™ DNA fragmentation detection kit was obtained
from Calbiochem (#QIA33), following instruction to perform TUNEL
assay. Brieﬂy, slides were treated with proteinase K (20 μg/mL) in
10 mM Tris–HCl (pH 8.0). Endogenous peroxidase was inactivated
through incubating the sections for 5 min in 3% H2O2. The slide
sections were covered in a moisture chamber for 1 h at 37 °C with
3.0 μl terminal deoxynucleotidyl transferase (TdT). The biotinylated
nucleotides were detected using a streptavidin-horseradish peroxi-
dase conjugate. Diaminobenzidine reacted with the labeled sample to
generate an insoluble colored substrate at the site of DNA fragmen-
tation. After the sections were counterstained with 0.3%methyl green,
the slides were then used in the morphological evaluation and
characterization of normal and apoptotic cells.
2.7. Western blotting assay
Protein samples weremade from cold RIPA buffer, boiled for 10 min
in Laemli sample buffer, resolved by 10% SDS-polyacrylamide gel
electrophoresis, transferred to nitrocellulose membrane, and blotted
with appropriate primary antibodies at dilution of 1: 500–1000.
Peroxidase-conjugated secondary antibodies were incubated at a
dilution of 1: 2000–3000. Bound antibody was visualized using
chemiluminescent substrate (ECL; AmershamBiosciences) and exposed
to Kodak X-Omat ﬁlm. β-actin was used as equal loading control.
2.8. Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated from hepatocytes with ready-to-use
TRIZOL Reagent (Gibco, Invitrogen). cDNA was synthesized from
1 μg of total RNA by use of the cDNA synthesis kit (Qiagen, Valencia,
CA). For qRT-PCR, gene was ampliﬁed with appropriate primer set in
triplicate. Level of gene expression was calculated by a mathematical
delta–delta method developed by PE Applied Biosystems. The level of
gene expression was normalized to the expression level of 18S rRNA.
2.9. Electrophoretic mobility shift assay (EMSA)
DIG Gel Shift Kit (Cat. No. 03 353 591 910, Roche) was used for
detecting sequence-speciﬁc DNA-binding proteins. Nuclear extracts
were prepared with the modiﬁed Dignam protocol [15]. 4 μg of
nuclear proteins and 2 μg of the nonspeciﬁc competitor poly [d(I–C)]
or poly [d(A–T)] were incubated with 20 fmol/μl DIG-labeled
oligonucleotides in binding buffer [100 mM Hepes, pH 7.6, 5 mM
Table 1
The potential nuclear binding sites may be regulators of iNOS expression. DNA-binding
domains are identiﬁed in the rat, mouse, and human iNOS promoter regions.
Name Total Sequencea Position in ratb In mousec In humand
C/EBPα 11
tcttttccaa –1782/−1773
gatgatgagt −995/−986
tgtcaatatt −921/−912 −963/−954 −440/−431
actttcataa −909/−900 −951/−942
aggaaattat −867/−858
ttgtttgttt −844/−835 −884/−875
ctttttttcc −441/−432 −1155/−1146
ctgcaaatga −379/−370
gtgacgtaat −170/−161
tgacgtaata −169/−160
ttgcacacc −119/−110 −133/−125
C/EBPβ 4
aagcaaagta −2082/−2073
actatctcac −1236/−1227
tgtgccacag −542/−533
tttatgcaaa −78/−69 −68/−59
C/EBPδ 1
aaatgagggt −576/−567
C/EBP-like 2
tttggaagca −1972/−1963
atttggaacc −455/−446
NF-κB 7
gtggctttcc −1746/−1737
gggattttcc −962/−953 −1004/−995
gattttccct −960/−951 −1002/−993
tggaaaatcc −899/−890
ggaaaatccc −898/−889
ggggactctc −105/−96 −119/−108
gggactctcc −104/−95 −118/−109
a Lower case letters represent the putative DNA sequence of iNOS promoter that is
potentially bound by nuclear factors.
b Rat iNOS accession number NM_012611.2.
c Mouse iNOS accession number NM_010927.2.
d Human iNOS accession number NM_000625.4.
Table 2
Oligonucleotide probes for electrophoretic mobility shift assay.
C/EBP α CTGTCAATATTTCACTTTCATAAT
C/EBP β CAGTGACTTTATGCAAAACAGCTC
NF-кb CCTACTGGGGACTCTCCCTTTG
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150 mMKCl]. Binding reactionswere achieved through incubating the
samples for 15 min at 22 °C. Protein–DNA complexes were separated
from the unbound DNA probe by electrophoresis through 6% native
polyacrylamide gels containing 0.5×Tris borate/EDTA.
2.10. Chromatin immunoprecipitation (ChIP) assay
ChIP assay was carried out as described [20]. Cells were homoge-
nized, ﬁxed in 10 ml 1% formaldehyde. The cell pellet was resuspended
in 2 ml Lysis Buffer (5 mM PIPES, 85 mM KCl, 0.5% NP-40, Protease
Inhibitor Cocktail, pH 8.0). The crude nuclear extract was re-suspended
in Lysis Buffer High Salt (1×PBS, 1% NP-40, 0.5% Sodium Deoxycholate,
0.1%SDS, and Protease Inhibitor Cocktail) and subsequently sonicated at
a power setting of 30%. For the immunoprecipitation, 4 μg of rabbit
antiserumwas used. Crosslinks were reversed on all samples, including
20% input, by addition of 400 μl Elution Buffer (1% SDS, 0.1 M NaHCO3).
DNA is extracted with an equal volume of phenol/chloroform/isoamyl
alcohol. 2 μl of a total 50 μl ChIP-DNAwas ampliﬁed using aMyiQ Single
Color Real-Time PCR Detection System (Bio-Rad).
2.11. Statistical analysis
All results represent at least three experiments using cells or
extracts from a minimum of three separate isolations. Data are
expressed as means±SD unless otherwise indicated. Comparisons
were performed using Student's t test or one-way analysis of variance
followed by Bonferroni correction where appropriate. Differences
were considered signiﬁcant at the 95% conﬁdence interval (pb0.05).
3. Results
3.1. iNOS gene promoter contains potential binding sites for C/EBPα,
C/EBPβ, and NF-κB
iNOS gene promoter includes putative nuclear protein binding sites.
Somebinding sites such asNF-κB and stat-1αhad been proved [21]. They
canact on the iNOSpromoter to regulate iNOSexpression.Otherpotential
binding sites and their function still need to be demonstrated. The iNOS
promoter region embodies conservative DNA-binding domains. A
similarity can be observed in the rat, mouse, and human genomes
(Table 1). Within −2.1 kb of the rat iNOS promoter upstream of the
transcription start site, there are 11 C/EBPα, 4 C/EBPβ, 1 C/EBPδ, 2 C/EBP-
like (do not belong to any C/EBP subgroup), and 7 NF-κB potential
binding sites, respectively. In this study we focused on the binding sites
of C/EBPα and C/EBPβ, with the known NF-κb as a positive reference.
Two rat NF-κB potential binding sites, with the DNA sequences being
gggactctcc (−104/−95) and ggggactctc (−105/−96), are overlapped in
onlyonenucleotidedifference. Another twoNF-κBpotential binding sites,
with sequences gattttccct (−960/−951) and gggattttcc (−962/−953),
have two nucleotide difference. All of them are conserved in the mouse.
The similar overlap zone occurs in rat C/EBPα potential binding siteswith
sequences tgacgtaata (−169/−160) and gtgacgtaat (−170/−161), but
sequences tgtcaatatt (−921/−912) and actttcataa (−909/−900) are
connected in series two nucleotides apart. The C/EBPα potential binding
sequence tgtcaatatt is completely conservative within rat, mouse, and
human genomes. iNOS promoter has potential binding sites for C/EBPα,
C/EBPβ, and NF-κB, which are evolutionarily conserved. Some binding
motifs may be regulators of the iNOS expression.
3.2. C/EBPα, C/EBPβ, and NF-κB can bind iNOS promoter as
demonstrated by EMSA
The multiple binding sites for C/EBPα, C/EBPβ, and NF-κB were
found in rat iNOS promoter region.We only chose the potential binding
domains with high conservation and near to the transcription start sitefor the following investigation. EMSAwas run to examinewhether these
nuclear proteins could directly bind iNOS promoter regions, based on
the differential mobility of free DNA and DNA-protein complexes in
non-denaturing polyacrylamide gel. Oligonucleotide probes contained
the identical sequences for C/EBPα, C/EBPβ, and NF-κb binding sites
were designed and optimized (Table 2). The probe sequences are 5′-
CCTACTGGGGACTCTCCCTTTG-3′ (NF-κb, -111/−90), 5′-CTGTCAA-
TATTTCACTTTCATAAT-3′ (C/EBPα, −922/−899), and 5′-CAGTGACTT-
TATGCAAAACAGCTC-3′ (C/EBPβ,−78/−69), inwhich the iNOS binding
consensus was underlined. Results showed all of these in vitro-
synthesized probes could bind nuclear proteins (Fig. 1). When
consistent antibody was added into probe/nuclear protein complex,
the binding signal was further inspected with gel super shift assay. The
gel super shift revealed similar results to EMSA (data not shown).
Through EMSAand gel super shift assay, we demonstrated there existed
speciﬁc DNA sequences in iNOS promoter to bind C/EBPα, C/EBPβ, or
NF-κB proteins, which suggested that the expression of iNOS might be
mediated by C/EBPα, C/EBPβ, or NF-κB nuclear proteins.
3.3. iNOS promoter is direct transcriptional targets of C/EBPα, C/EBPβ,
and NF-κB as determined by ChIP assay
In order to ﬁnd more evidence about the relationship between
iNOS and nuclear proteins, ChIP assay was carried out to determine
Fig. 1. Through the electrophoretic mobility shift assay, the three in vitro-synthesized
oligonucleotide probes could bind identical nuclear proteins.
1398 K. Wang et al. / Biochimica et Biophysica Acta 1813 (2011) 1395–1403nuclear protein/DNA binding ability in their native chromatin context.
Hepatocytes were homogenized in sterile cold PBS and ﬁxed in
formaldehyde to form protein:DNA complexes. The chromatin was
then mechanically sheared by sonication to generate small protein:
DNA fragments. These fragments were immunoprecipitated with
antibodies speciﬁc for the nuclear protein or rabbit IgG as negative
control. Immunoprecipitated protein was subjected to Western blot
analysis to test whether the protein was antibody-speciﬁc (Fig. 2A).
After reversing the cross-links and removing proteins from the
immunoprecipitated protein:DNA complexes, the DNA samples
were isolated. The puriﬁed DNA was analyzed by primers to cover
potential regulatory regions (Table 3). The relative ratios from speciﬁc
antibody/IgG could reﬂect the results of ChIP assay for NF-κb, C/EBPα,
and C/EBPβ, respectively (Fig. 2B, C and D). The expression of iNOS
could be modulated with C/EBPα, C/EBPβ, and NF-κB binding
proteins.Fig. 2. A. Immunoprecipitatedproteinwas subjected toWesternblot analysis. B, C, D. The relativ
and C/EBPβ, respectively. *Pb0.01 speciﬁc antibody vs. IgG antibody.3.4. Site-directed mutagenesis of NF-κB, C/EBPα, and C/EBPβ binding
sites in the iNOS promoter
To conﬁrm the differential effect of every potential binding site on
the iNOS promoter, a speciﬁc site was deleted and then the activity of
the mutated iNOS promoter was measured with luciferase reporter
assay. Site-directed mutagenesis at NF-κb, C/EBPα, or C/EBPβ binding
siteswereperformed in the iNOSpromoter anddesignated asmt-NF-κb,
mt-C/EBPα-A, mt-C/EBPα-B, mt-C/EBPα-AB, and mt-C/EBPβ, respec-
tively. The deleted DNA fragments in the iNOS promoter region were
exactly identical to the sequence of C/EBPα, C/EBPβ, or NF-κB binding
sites (Table 4). For the luciferase assay, HepG2 cells were transfected
with 2 μg of each luciferase vector for 36 h. The deletions of NF-κb,
C/EBPα, or C/EBPβ binding sites signiﬁcantly altered iNOS promot-
er activity in different degrees (Fig. 3). According to data from
EMSA, super gel shift, ChIP assay, and site-directed mutagenesis, it
is concluded that iNOS is regulated by transcription factor C/EBPα,
C/EBPβ, and NF-κB.
3.5. Effect of NF-κB inhibition
Because the deletion of NF-κb binding site signiﬁcantly decreased
iNOS promoter activity (Fig. 3), we therefore treated the primary
hepatocytes with NF-κb inhibitor BAY 11-7082 to investigate the role
of NF-κb following the utilization of the NF-κb inhibitor. The BAY 11-
7082 decreased NF-κb-DNA binding activity as demonstrated through
EMSA with oct1 as control (Fig. 4A). Also, the activation of NF-κb
could be indirectly represented by IκB degradation as shown by
Western blotting of IκBα protein (Fig. 4B). When NF-κb was brought
down, the expression of iNOS was down-regulated as proved through
qRT-PCR and Western blotting (Fig. 4C and D). These results clearly
showed that NF-κB was a mediator for the expression of the iNOS in
rat hepatocytes. Moreover, NF-κB inhibitor BAY 11-7082 not only
reduced iNOS, but also altered C/EBPα- and C/EBPβ-DNA binding
abilities (Fig. 4E). Levels of C/EBPβ and C/EBPα were measured with
real-time PCR (Fig. 4F and G). The BAY 11-7082 could up-regulate C/
EBPα, but down-regulate C/EBPβ expression through an unknowne ratios fromspeciﬁc antibody/IgG could reﬂect the results of ChIP assay for NF-κb, C/EBPα,
Table 3
Primers for ChIP assay.
NF-kB Forward TGGGGACCAGGAAGAGGTGGC
Reverse GCTGTGGCCCTGACAGTAGCC
C/EBP α Forward GTGGACCCTGGCGGGATATGC
Reverse ACAGATCCCTGAGTTTGGGCCAGT
C/EBP β Forward GAGGCCACTCGCTGCCAAGG
Reverse GTCCCGTGGGGCCAGAGTCT
Table 4
The deleted codes for site-directed mutagenesis in rat iNOS promoter.
NF-кb GGGGACTCTC
C/EBPβ TTTATGCAAA
C/EBPα-A TGTCCATATT
C/EBPα-B TTGCACACC
C/EBPα-AB TGTCAATATT and TTGCACACC
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and C/EBPα or C/EBPβ.
3.6. iNOS expression following the transfection of C/EBPα and C/EBPβ
siRNAs
As C/EBPα or C/EBPβ was silenced by individual siRNA (Fig. 5A),
iNOS was up-regulated by C/EBPα siRNA and down-regulated by C/
EBPβ siRNA (Fig. 5B and C). We do not know what causes these
opposite effects subsequent to the transfection of C/EBPα and C/EBPβ
siRNAs at present. A further investigation is under way, in order to
clarify how C/EBPα/C/EBPβ to regulate the iNOS expression.
3.7. C/EBPα and C/EBPβ can regulate GCDC-induced apoptosis
GCDC induced apoptosis in hepatocytes. The iNOS level modiﬁed
the proﬁle of GCDC-induced hepatocyte apoptosis as demonstrated by
the iNOS-speciﬁc inhibitor 1400 W (Fig. 6A and B). Because the
expression of iNOS was stimulated by the transfection of C/EBPα
siRNA and reduced by C/EBPβ siRNA (Fig. 5B and C), we thus supposed
that C/EBPα/C/EBPβ might affect the apoptotic process of GCDC-
treated hepatocytes through the iNOS pathway. To demonstrate this
hypothesis, we treated hepatocytes with iNOS inhibitor 1400 W
(50 μM) or transfection of C/EBPα or C/EBPβ siRNA for 16 h.
Thereafter hepatocytes were challenged with GCDC for another 4 h.
The hepatocyte apoptosis was reﬂected with caspase-3 activity and
TUNEL assay (Fig. 6C,D, E and F).As expected, the transfection of C/EBPα
or C/EBPβ siRNA could alter the GCDC-induced apoptosis. The effects ofFig. 3. The HepG2 cells were transfected with various iNOS promoter constructs.
Intracellular luciferase activities were determined and normalized to the activity of
control vector. Data represent mean±SD of four different experiments. *Pb0.05;
**Pb0.01 deletion vs. non-deletion.C/EBPα or C/EBPβ siRNAs were eliminated by iNOS inhibitor 1400W.
Through the iNOS signaling pathway, C/EBPα/C/EBPβ played a
regulatory role during the GCDC-induced apoptosis in hepatocytes.
4. Discussion
Our data demonstrate the endogenous iNOS is regulated by cis-
acting elements such as C/EBPα, C/EBPβ, and NF-κB binding sites.
C/EBPα down-regulates the iNOS expression, whereas C/EBPβ up-
regulates the iNOS expression. The molecular basis for this observa-
tion remains unknown. The inhibition of NF-κB mediates the
expression of C/EBPα and C/EBPβ. There is a certain relationship
between NF-κB and C/EBPα/C/EBPβ transcription factors, but the
mechanismneeds to be scrutinized. Both C/EBPα and C/EBPβ binding
proteins modulate the GCDC-induced apoptosis in hepatocytes
through the iNOS signaling pathway. We do not know if C/EBPs —
iNOS is the only pathway to regulate the GCDC-induced hepatocyte
apoptosis. Considering the complicated regulation and various
effects of C/EBPs [22], no simple rule governs the mechanism of
transcriptional regulation in iNOS expression. The pathway of C/EBPs—
iNOS may be one connection of multiple regulatory networks.
Furthermore, the anti-apoptotic ability of the endogenous iNOS is
limited. The high concentration of GCDC or low concentration of GCDC
in long time exposure can completely neutralize the resistance of the
endogenous iNOS. A continued advancewill yield new insights on iNOS
role during hepatocyte apoptosis.
The iNOS expression is controlled by a variety of mechanisms that
can be classiﬁed into one of these four categories: transcriptional,
posttranscriptional, translational, and posttranslational [23]. Nuclear
transcription factors such as C/EBPs bind to speciﬁc base sequences
within regions of the promoter and the enhancer to mediate gene
transcription. The coordinated expression of different C/EBPs consti-
tutes a critical component of the tissue-speciﬁc and cell stage-speciﬁc
functions [24]. Modular protein C/EBPswere consisted of an activation
domain, DNA binding domain, and leucine zipper dimerization region.
C/EBPα and C/EBPβ are made of multiple polypeptides [25]. All C/EBP
proteins contain a highly conserved C-terminal basic region-leucine
zipper (bZIP) DNA binding domain, which can bind as homo- or
hetero-dimers to certain promoters and enhancers. The bZIP domain
via the adjacent basic regions also mediates a large number of the
protein–protein interactions [26]. The N-terminal domains of C/EBPs
are rather diverse, which are involved in contact with the basal
transcriptional apparatus (TBP/TFIIB), transcriptional coactivators
(CBP/p300), and sumoylation [27–29]. C/EBPα and C/EBPβ have
multiple functions. C/EBPα binds to the promoter to facilitate the
expression of the genes such as leptin, a protein that plays an
important role in body weight homeostasis [30]. Also, the C/EBPα can
interact with CDK2 and CDK4, thereby inhibiting these kinases and
causing growth arrest [31]. The co-crystal structure of the C/EBPα
bZIP domain is a continuous α-helix with residues 286–300 entering
the major groove to make direct contact with the base pairs and the
phosphate backbone [32]. Phosphorylation of C/EBPα serine 21 by
extracellular signal-regulated kinase suppresses its activity [33].
Constitutive expression of C/EBPβ is highest in the liver and lung
and is also detectable in other tissues such as kidney, heart, and
spleen. Stimulation with LPS, IL-6, or IL-1 strongly induces C/EBP
expression in cultured cells, suggesting a potential C/EBP role in the
mediation of the inﬂammatory response [34]. The transcription
factors search along the DNA strand for promoter regions and the
enhancer region, which bind and create a special cubic structure.
Thereafter, this molecular conformation is recognized by RNA
polymerase [35]. The transcription factors are imperative for RNA
polymerase to attach, which is an important mechanism to regulate
the gene expression. A lot of transcription factors have been
discovered; each recognizes and binds with a speciﬁc nucleotide
sequence in the DNA [36]. A speciﬁc combination of transcription
Fig. 4. A. The BAY 11-7082 decreased NF-κb-DNA binding activity as demonstrated through EMSA with oct1 as control. B. The activation of NF-κb could be indirectly represented
by IκB degradation as shown by Western blotting of IκBα protein. C, D. After NF-κb was inhibited, the expression of iNOS was down-regulated as proved with Western blotting and
qRT-PCR, *Pb0.05. E. NF-κB inhibitor BAY 11-7082 reduced iNOS as well as altered C/EBPα- and C/EBPβ-DNA binding abilities. F, G. Expression of C/EBPβ and C/EBPαweremeasured
with real-time PCR following BAY 11-7082 treatment. *Pb0.01 no BAY 11-7082 vs. Bay11-7082.
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tion factors. Their function has been investigated in other cells, such as
adipocytes, myeloid cells, lung epithelium, and so on [37,38]. This
study uncovers C/EBPα has an opposite effect caused by C/EBPβ in the
regulation of iNOS expression. Perhaps C/EBPα can work with the
binding motifs of iNOS promoter to inhibit the attachment of RNA
polymerase, whereas C/EBPβ stimulates the attachment of RNA
polymerase and triggers an activation of transcription. Certainly,
this hypothesis needs supports from the alternation of molecular
conformation.
iNOS is included in complex immunomodulatory and inﬂamma-
tory mechanisms [39]. iNOS expression can be induced in many cell
types with suitable agents such as bacterial lipopolysaccharides,
cytokines, and other compounds. iNOS can also be inhibited by a widevariety of immunomodulatory compounds [40]. iNOS is regulated
very tightly. Modulation on both the transcriptional and post-
transcriptional level is the major regulation mechanism for iNOS
expression [41]. Cis-controlling elements and transcription factors are
associated with iNOS expression. In the human iNOS promoter,
mutation of a C/EBPβ-binding site within the region from−365 to the
transcription initiation site markedly decreased the promoter activity
[42]. C/EBPβ participated in DNA-protein complex formation and
involved the activation of the human iNOS promoter by IL-1β [43].
Changes in the relative expression of different C/EBPs may affect
global changes in hepatocyte gene expression, which can promote or
inhibit hepatocyte survival. C/EBPβ is important in modulating the
expression of various acute phase response genes such as iNOS. The
activity of iNOS/NO is increased in hepatocytes during the mid-late
Fig. 5. A. Effective knockdown of C/EBPα or C/EBPβ was conﬁrmed by Western blot analysis. B, C. The levels of iNOS were determined subsequent to C/EBPα or C/EBPβ siRNA
treatment. *Pb0.05; **Pb0.01 scrambled RNA vs. siRNA.
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been shown to inhibit caspase-3 activation by TNFα [6]. Considering
the pivotal role of caspase-3 in apoptosis, C/EBPβ-mediated NO
productionmay be one of themechanisms that prevent injury-related
cytokines from causing hepatocyte apoptosis [7]. Our data about C/
EBPs and iNOS were derived from rat primary hepatocytes, but these
results were similar to those in other tissues or cells. Vascular
endothelium participates in the control of vascular tone and function.
iNOS expression, following induction by lipopolysaccharide or
cytokines, results in endothelial cell activation and dysfunction. In
rat pulmonary microvascular endothelial cells, C/EBP sites within the
−205/+88 region are responsible for induction of the iNOS promoter.
There is an intricate interaction between C/EBPs and NF-κB.
Mutation results show that mt- NF-κB and mt- C/EBPβ decreased the
luciferase activities and mt- C/EBPα-AB signiﬁcantly increased the
promoter activity. However single mutation mt-C/EBPα-A or mt-C/
EBPα-B did not alter the promoter activity. These data reveal the iNOS
promoter has multiple cis-acting elements. Theses regulatory sites are
interrelated and interact with each other to balance iNOS expression.
Single C/EBPα mutation does not change promoter activity, suggest-
ing either the presence of compensatory mechanisms masking the
importance of C/EBPα loss or the likelihood that some C/EBPα sites
are not essential to the promoter function. Two or more simultaneous
mutations in C/EBPα sites can cause an alternation of the molecular
conformation or cubic structure [38,43,45]. It is hardly surprising to
get a substantial change in iNOS promoter function. In another study,
mutations of the C/EBPβ- and NF-κB-binding site signiﬁcantly
decreased the iNOS promoter activity, but the iNOS promoter was
activated subsequent to transfection of C/EBPβ liver-enriched activa-
tor protein and NF-κB. C/EBPβ stimulates iNOS gene expression
synergistically with NF-κB in primary rat hepatocytes [42]. The human
iNOS promoter is activated by IL-1β, which are regulated by C/EBP
along with NF-κB binding sites in rat pulmonary microvascular
endothelial cells [43]. Signaling pathways of iNOS expression vary in
different cells or species, but activation of NF-κB and thereby
activation of the iNOS promoter seems to be an essential step for
the iNOS induction [21]. The interaction between C/EBPs and NF-κB is
also seen in other tissues. C/EBPβ and NF-κB cooperatively bind andactivate the IL-6, IL-8, G-CSF, serum amyloid, intercellular adhesion
molecule 1, superoxide dismutase and Mediterranean fever pro-
moters during the inﬂammatory response in myeloid and other cells
[26]. C/EBPα or C/EBPβ is interacted with translated p50 or p65,
mapping to the bZIP domain of C/EBP and to the Rel homology domain
of p65 [46]. C/EBPα or C/EBPβ works with NF-κB p50 to induce bcl-2
transcription and inhibit apoptosis in hematopoietic cells [47]. A further
study is still needed to elucidate the interaction between NF-κB and
C/EBPs in hepatocytes.
Hepatocyte apoptosis is an essential change in hepatic pathology
following various etiological factors such as viruses, alcohol, chole-
stasis, etc. [48]. For the treatment of hepatic injury, an effective
method is to decrease or inhibit apoptosis in hepatocytes. C/EBP
binding proteins could affect the hepatocyte apoptosis through the
iNOS signaling pathway, which provided an important target to block
apoptosis. However, this is a complicated process. The role of C/EBPs is
required to be demonstrated in vivo study, because of complex
regulation and the multiple effects of C/EBPs. Liver is rich with C/EBPs.
Liver function is inﬂuenced by the levels of C/EBPs [49]. It is likely to
improve the liver function through an intervention of C/EBPs — iNOS
pathway. The present data show a possibility to link the basic research
with the clinical relevance. GCDC-induced hepatocyte injury occurs in
many hepatic diseases such as cholestatic disorder, hapertitis, primary
sclerosing cholangitis, and so on [18], but the current treatments are
less effective in clinical practice. The study on C/EBPs— iNOS signaling
in hepatocytes aims at ﬁnding an effective approach for the treatment
of toxic bile-induced liver injury. Several studies have provided useful
information. Hypoxia enhanced rat iNOS promoter activity, but this
hypoxia-induced promoter activity was abolished by the disruption of
a C/EBP motif at−910 through substitution of GG for AA at−904 to
−903 as well as deletion of −914 to −905 [50]. Human iNOS gene
was transcriptionally regulated by IL-1β in rat pulmonary microvas-
cular endothelial cells. C/EBP sites located downstream of −205 are
involved in the activation of the human iNOS promoter by IL-1β [43].
The silencing of the C/EBPβ binding site may regulate inﬂammatory/
immune response through the iNOS pathway.
The present data were obtained from rat primary hepatocytes.
These results need to be further conﬁrmed by means of in vivo animal
Fig. 6. A. 6B GCDC induced apoptosis in hepatocytes, but iNOS-speciﬁc inhibitor 1400 W (50 μM) altered the proﬁle of GCDC-caused hepatocyte apoptosis as demonstrated with
caspase-3 activity and TUNEL assay *Pb0.05; **Pb0.01. C, D, E, F. Hepatocytes were treated with iNOS inhibitor 1400 W or transfected with C/EBPα or C/EBPβ siRNAs for 16 h.
Thereafter cells were challenged with GCDC for another 4 h. The hepatocyte apoptosis was reﬂected with caspase-3 activity and TUNEL assay. The transfection of C/EBPα or C/EBPβ
siRNAs could affect the GCDC-induced apoptosis, but the effects of C/EBPα or C/EBPβ siRNAs were eliminated by iNOS inhibitor 1400 W.
1402 K. Wang et al. / Biochimica et Biophysica Acta 1813 (2011) 1395–1403studies such as bile duct ligation, hemihepatectomy, or other
compound-induced liver injury models. The challenge lies in testing
the feasibility, efﬁcacy, and reliability in individual model. In
summary, the C/EBPα and C/EBPβ binding proteins regulate the
expression of iNOS. Through iNOS signaling pathway, the GCDC-
induced apoptosis in hepatocytes is furthermore modulated. These
data suggest that the C/EBPs/iNOS signaling pathways have a
potential value in the treatment of hepatocyte apoptosis.Acknowledgements
This work was supported in part by the Falk Medical Research
Foundation grant and National Institute of Health grant R21DK070784-02. We appreciated Xiao Wang's help during preparation
of the manuscript.
References
[1] W.W. Chang, I.J. Su, W.T. Chang, W. Huang, H.Y. Lei, Suppression of p38 mitogen-
activated protein kinase inhibits hepatitis B virus replication in human hepatoma
cell: the antiviral role of nitric oxide, J. Viral Hepat. 15 (7) (2008) 490–497.
[2] J. Abrams, Beneﬁcial actions of nitrates in cardiovascular disease, Am. J. Cardiol. 77
(13) (1996) 31–37.
[3] F. Yaylak, H. Canbaz, M. Caglikulekci, M. Dirlik, L. Tamer, Z. Ogetman, Y. Polat, A.
Kanik, S. Aydin, Liver tissue inducible nitric oxide synthase (iNOS) expression and
lipid peroxidation in experimental hepatic ischemia reperfusion injury stimulated
with lipopolysaccharide: the role of aminoguanidine, J. Surg. Res. 148 (2) (2008)
214–223.
[4] B.S. Taylor, L.H. Alarcon, T.R. Billiar, Inducible nitric oxide synthase in the liver:
regulation and function, Biochemistry (Mosc). 63 (7) (1998) 766–781.
1403K. Wang et al. / Biochimica et Biophysica Acta 1813 (2011) 1395–1403[5] J. Li, C.A. Bombeck, S. Yang, Y.M. Kim, T.R. Billiar, Nitric oxide suppresses apoptosis
via interrupting caspase activation and mitochondrial dysfunction in cultured
hepatocytes, J. Biol. Chem. 274 (24) (1999) 17325–17333.
[6] Y.M. Kim, C.A. Bombeck, T.R. Billiar, Nitric oxide as a bifunctional regulator of
apoptosis, Circ. Res. 84 (3) (1999) 253–256.
[7] Y.M. Kim, T.H. Kim, H.T. Chung, R.V. Talanian, X.M. Yin, T.R. Billiar, Nitric oxide
prevents tumor necrosis factor alpha-induced rat hepatocyte apoptosis by the
interruption of mitochondrial apoptotic signaling through S-nitrosylation of
caspase-8, Hepatology 32 (4 Pt 1) (2000) 770–778.
[8] J.E. Albina, S. Cui, R.B. Mateo, J.S. Reichner, Nitric oxide-mediated apoptosis in
murine peritoneal macrophages, J. Immunol. 150 (11) (1993) 5080–5085.
[9] Y.J. Lee, K.H. Lee, H.R. Kim, J.M. Jessup, D.W. Seol, T.H. Kim, T.R. Billiar, Y.K. Song,
Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-
dependent pathway in human colorectal carcinoma CX-1 cells, Oncogene 20 (12)
(2001) 1476–1485.
[10] J. Liu, M.P.Waalkes, Nitric oxide and chemically induced hepatotoxicity: beneﬁcial
effects of the liver-selective nitric oxide donor, V-PYRRO/NO, Toxicology 208 (2)
(2005) 289–297.
[11] H. Miyoshi, C. Rust, M.E. Guicciardi, G.J. Gores, NF-kappaB is activated in
cholestasis and functions to reduce liver injury, Am. J. Pathol. 158 (3) (2001)
967–975.
[12] D.A. Geller, P.D. Freeswick, D. Nguyen, et al., Differential induction of nitric oxide
synthase in hepatocytes during endotoxemia and the acute-phase response, Arch.
Surg. 129 (2) (1994) 165–171.
[13] T. Chen, R. Zamora, B. Zuckerbraun, T.R. Billiar, Role of nitric oxide in liver injury,
Curr. Mol. Med. 3 (6) (2003) 519–526.
[14] C. Bernt, T. Vennegeerts, U. Beuers, C. Rust, The human transcription factor AP-1 is
a mediator of bile acid-induced liver cell apoptosis, Biochem. Biophys. Res.
Commun. 340 (3) (2006) 800–806.
[15] K. Wang, J.J. Brems, R.L. Gamelli, J. Ding, Reversibility of caspase activation and its
role during glycochenodeoxycholate-induced hepatocyte apoptosis, J. Biol. Chem.
280 (25) (2005) 23490–23495.
[16] P.O. Seglen, Preparation of isolated rat liver cells, Methods Cell Biol. 13 (1976)
29–83.
[17] V. Gavrilyuk, P. Horvath, G. Weinberg, D.L. Feinstein, A 27-bp region of the
inducible nitric oxide synthase promoter regulates expression in glial cells, J.
Neurochem. 78 (1) (2001) 129–140.
[18] K. Wang, P.V. Subbaiah, Importance of the free sulfhydryl groups of lecithin-
cholesterol acyltransferase for its sensitivity to oxidative inactivation, Biochim.
Biophys. Acta 1488 (3) (2000) 268–277.
[19] G. Pilon, P. Dallaire, A. Marette, Inhibition of inducible nitric-oxide synthase by
activators of AMP-activated protein kinase: a newmechanism of action of insulin-
sensitizing drugs, J. Biol. Chem. 279 (20) (2004) 20767–20774.
[20] K. Wang, J.J. Brems, R.L. Gamelli, A.X. Holterman, Survivin signaling is regulated
through nuclear factor-kappa B pathway during glycochenodeoxycholate-induced
hepatocyte apoptosis, Biochim. Biophys. Acta. 1803 (12) (2010) 1368–1375.
[21] A. Pautz, J. Art, S. Hahn, S. Nowag, C. Voss, H. Kleinert, Regulation of the expression
of inducible nitric oxide synthase, Nitric Oxide 23 (2) (2010) 75–93.
[22] C. Nerlov, Transcriptional and translational control of C/EBPs: the case for “deep”
genetics to understand physiological function, Bioessays 32 (8) (2010) 680–686.
[23] K.M. Rao, Molecular mechanisms regulating iNOS expression in various cell types,
J. Toxicol. Environ. Health B Crit. Rev. 3 (1) (2000) 27–58.
[24] R. Yamanaka, J. Lekstrom-Himes, C. Barlow, A. Wynshaw-Boris, K.G. Xanthopoulos,
CAAT/enhancer binding proteins are critical components of the transcrip-
tional regulation of hematopoiesis (Review), Int. J. Mol. Med. 1 (1) (1998)
213–221.
[25] D.P. Ramji, P. Foka, CCAAT/enhancer-binding proteins: structure, function and
regulation, Biochem. J. 365 (Pt 3) (2002) 561–575.
[26] A.D. Friedman, Transcriptional control of granulocyte and monocyte develop-
ment, Oncogene 26 (2007) 6816–6828.[27] Nerlov, E.B. Ziff, CCAAT/enhancer binding protein-alpha amino acid motifs with
dual TBP and TFIIB binding ability co-operate to activate transcription in both
yeast and mammalian cells, EMBO J. 14 (1995) 4318–4328.
[28] Mink B. Haenig, K.H. Klempnauer, Interaction and functional collaboration of p300
and C/EBPbeta, Mol. Cell. Biol. 17 (1997) 6609–6617.
[29] J. Kim, C.A. Cantwell, P.F. Johnson, C.M. Pfarr, S.C.Williams, Transcriptional activity
of CCAAT/enhancer-binding proteins is controlled by a conserved inhibitory
domain that is a target for sumoylation, J. Biol. Chem. 277 (2002) 38037–38044.
[30] S.G. Miller, P. De Vos, M. Guerre-Millo, K. Wong, T. Hermann, B. Staels, M.R. Briggs, J.
Auwerx, The adipocyte speciﬁc transcription factor C/EBPalphamodulates humanob
gene expression, Proc. Natl. Acad. Sci. U. S. A. 93 (11) (1996) 5507–5511.
[31] H. Wang, P. Iakova, M. Wilde, A. Welm, T. Goode, W.J. Roesler, N.A. Timchenko, C/
EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4,
Mol. Cell (4) (2001) 817–828.
[32] M. Miller, J.D. Shuman, T. Sebastian, Z. Dauter, P.F. Johnson, Structural basis for
DNA recognition by the basic region leucine zipper transcription factor CCAAT/
enhancer-binding protein alpha, J. Biol. Chem. 278 (17) (2003) 15178–15184.
[33] S.E. Ross, H.S. Radomska, B. Wu, P. Zhang, J.N. Winnay, L. Bajnok, W.S. Wright, F.
Schaufele, D.G. Tenen, O.A. MacDougald, Phosphorylation of C/EBPalpha inhibits
granulopoiesis, Mol. Cell. Biol. 24 (2) (2004) 675–686 Jan.
[34] Z. Guo, L. Shao, X. Feng, K. Reid, E. Marderstein, A. Nakao, D.A. Geller, A critical role
for C/EBPbeta binding to the AABS promoter response element in the human iNOS
gene, FASEB J. (12) (2003) 1718–1720.
[35] D. Beyersmann, Regulation of mammalian gene expression, EXS 89 (2000) 11–28.
[36] H. Sutherland, W.A. Bickmore, Transcription factories: gene expression in unions?
Nat. Rev. Genet. 10 (7) (2009) 457–466.
[37] C. Nerlov, Transcriptional and translational control of C/EBPs: the case for “deep”
genetics to understand physiological function, Bioessays 32 (8) (2010) 680–686.
[38] D.P. Ramji, P. Foka, CCAAT/enhancer-binding proteins: structure, function and
regulation, Biochem. J. 365 (Pt 3) (2002) 561–575.
[39] J.R. Kanwar, R.K. Kanwar, H. Burrow, S. Baratchi, Recent advances on the roles of
NO in cancer and chronic inﬂammatory disorders, Curr. Med. Chem. 16 (19)
(2009) 2373–2394.
[40] H. Kleinert, P.M. Schwarz, U. Förstermann, Regulation of the expression of
inducible nitric oxide synthase, Biol. Chem. 384 (10–11) (2003) 1343–1364.
[41] N. Schmidt, A. Pautz, J. Art, P. Rauschkolb, M. Jung, G. Erkel, M.B. Goldring, H.
Kleinert, Transcriptional and post-transcriptional regulation of iNOS expression in
human chondrocytes, Biochem. Pharmacol. 79 (5) (2010) 722–732.
[42] K. Sakitani,M. Nishizawa, K. Inoue, Y. Masu, T. Okumura, S. Ito, Synergistic regulation
of inducible nitric oxide synthase genebyCCAAT/enhancer-bindingprotein beta and
nuclear factor-kappaB in hepatocytes, Genes Cells 3 (5) (1998) 321–330.
[43] A.Y. Kolyada, N.E. Madias, Transcriptional regulation of the human iNOS gene by
IL-1beta in endothelial cells, Mol. Med. 7 (5) (2001) 329–343.
[44] R.M. Rai, F.Y. Lee, A. Rosen, S.Q. Yang, H.Z. Lin, A. Koteish, F.Y. Liew, C. Zaragoza, C.
Lowenstein, A.M. Diehl, Impaired liver regeneration in inducible nitric oxide
synthasedeﬁcient mice, Proc. Natl. Acad. Sci. U. S. A. 95 (23) (1998) 13829–13834.
[45] C. Punzalan, C. Cai, R.A. Schroeder, P.C. Kuo, Redox regulation of the rat hepatocyte
iNOS promoter, Surgery 126 (2) (1999) 450–455.
[46] B. Stein, P.C. Cogswell, A.S. Baldwin Jr., Functional and physical associations
between NF-nB and C/EBP family members: a Rel domain-bZIP interaction, Mol.
Cell. Biol. 13 (1993) 3964–3974.
[47] I. Paz-Priel, D.H. Cai,D.Wang, J. Kowalski, A.Blackford,H. Liu, et al., C/EBPa andC/EBPa
myeloid oncoproteins induce Bcl-2 via interaction of their basic regions with NF-kB
p50, Mol. Cancer Res. 3 (2005) 585–596.
[48] H. Malhi, M.E. Guicciardi, G.J. Gores, Hepatocyte death: a clear and present danger,
Physiol. Rev. 90 (3) (2010) 1165–1194.
[49] N.A. Timchenko, Aging and liver regeneration, Trends Endocrinol. Metab. (4) (2009)
171–176.
[50] X. Teng,D. Li, J.D. Catravas, R.A. Johns, C/EBP-betamediates iNOS induction by hypoxia
in rat pulmonary microvascular smooth muscle cells, Circ. Res. 90 (2002) 125–127.
